GC
NTLA icon

GMT Capital’s Intellia Therapeutics NTLA Stock Holding History

GMT Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-330,533
Closed -$6.35M – 113
2017
Q4 		$6.35M Hold
330,533
– – 0.13% 80
2017
Q3 		$8.21M Buy
+330,533
New +$6.23M 0.16% 86
2017
Q2 		– Sell
-330,533
Closed -$4.66M – 104
2017
Q1 		$4.66M Buy
+330,533
New +$4.44M 0.1% 89

Other funds holding NTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

GMT Capital's NTLA Position: Q1 2018 in Review

GMT Capital sold out of Intellia Therapeutics (NTLA) in Q1 2018, closing a stake of 330,533 shares — an estimated $6.35M sold.

GMT Capital first reported a position in NTLA in Q1 2017 and held it in 3 quarters. The position peaked at $8.21M in Q3 2017. 130 funds tracked by Wall St. Rank hold NTLA as of Q1 2018.

  • GMT Capital reported no remaining Intellia Therapeutics position as of Q1 2018 after selling out during the quarter.
  • GMT Capital sold 330,533 Intellia Therapeutics shares in Q1 2018, an estimated $6.35M.
  • GMT Capital first reported a position in Intellia Therapeutics in Q1 2017 and held it in 3 quarters.
  • GMT Capital's Intellia Therapeutics position peaked at $8.21M in Q3 2017.
  • 130 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2018.

Based on GMT Capital's 13F filing for Q1 2018, filed 15 May 2018.